EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective

Kemal C Gogebakan, Natalia Kunst, Alireza Ghodsi, Lukas Owens, Amir Iravani, Ruth Etzioni

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.271825 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Kemal C Gogebakan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington; kgogebak@fredhutch.org. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Taxoids, Cost-Benefit Analysis, Dipeptides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The TheraP trial demonstrated that 177Lu-PSMA-617 improved progression-free survival (PFS) compared with cabazitaxel, with no significant difference in overall survival (OS). However, 177Lu-PSMA-617 was associated with fewer severe adverse events, better patient-reported outcomes, and lower health care utilization rates. In this study, we evaluated the impact of these benefits on the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective.

Methods

A partitioned survival model was developed to estimate lifetime costs and health outcomes associated with 177Lu-PSMA-617 versus cabazitaxel over a 60-mo horizon. OS and PFS associated with177Lu-PSMA-617 were derived from a retrospective cohort, and relative treatment effects (hazard ratios [HRs]) from the TheraP trial were applied to generate outcomes for patients treated with cabazitaxel. Health state utilities, adverse-event disutilities, and costs were obtained from published sources. Outcomes included total costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio, and net monetary benefit at willingness-to-pay (WTP) thresholds up to $200,000/QALY.

Results

In the base case analysis, 177Lu-PSMA-617 was not cost-effective compared with cabazitaxel (incremental cost-effectiveness ratio, $358,990/QALY). Cost-effectiveness results were most sensitive to the OS HR, the per-cycle cost of 177Lu-PSMA-617, and the per-cycle cost of cabazitaxel. 177Lu-PSMA-617 would become cost-effective if the per-cycle treatment cost was $27,656 or if the OS HR improved to 0.76 at a WTP threshold of $200,000/QALY. Probabilistic analyses found that 177Lu-PSMA-617 was cost-effective in 19.7% of iterations at a WTP threshold of $200,000/QALY, 4.7% at $100,000/QALY, and 2.2% at $50,000/QALY.

Conclusion

Although 177Lu-PSMA-617 was not cost-effective compared with cabazitaxel in the base case analysis, it may achieve cost-effectiveness under more favorable assumptions of survival benefit or reduced cost per cycle. Probabilistic analyses further highlighted substantial uncertainty, with a low likelihood of cost-effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Effectiveness AnalysisTaxoidsCost-Benefit AnalysisDipeptidesHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantHumansMaleUnited StatesLutetiumNeoplasm MetastasisRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu-PSMA-617PSMAcost-effectiveness analysismCRPCprostate cancerradiopharmaceutical therapy

Substanzen

cabazitaxelTaxoidsDipeptidesHeterocyclic Compounds, 1-RingLutetiumPSMA-617Radioisotopeslutetium (177Lu) vipivotide tetraxetanProstate-Specific Antigen

Autor:innen und Institutionen

  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington; kgogebak@fredhutch.org.
  • Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven,Connecticut.
  • Division of Nuclear Medicine, Department of Radiology, University of Washington School of Medicine, Seattle, Washington; and.
  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Fred Hutchinson Cancer Center, Seattle, Washington.

Förderung

  • NCI NIH HHS

Zitieren

APA

Gogebakan, K. C., Kunst, N., Ghodsi, A., Owens, L., Iravani, A., & Etzioni, R. (2026). Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271825

Vancouver

Gogebakan KC, Kunst N, Ghodsi A, Owens L, Iravani A, Etzioni R. Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271825

BibTeX
@article{Gogebakan2026,
  author = {Gogebakan, Kemal C and Kunst, Natalia and Ghodsi, Alireza and Owens, Lukas and Iravani, Amir and Etzioni, Ruth},
  title = {Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.271825}
}
Kostenlos starten →